MiNK Therapeutics Q2 2024 GAAP EPS $(0.07) Beats $(0.10) Estimate
Portfolio Pulse from Benzinga Newsdesk
MiNK Therapeutics (NASDAQ:INKT) reported a Q2 2024 GAAP EPS of $(0.07), beating the analyst consensus estimate of $(0.10) by 30%.
August 13, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MiNK Therapeutics reported a Q2 2024 GAAP EPS of $(0.07), which is better than the analyst consensus estimate of $(0.10). This positive earnings surprise could lead to a short-term increase in the stock price.
The company's reported EPS was significantly better than expected, which is generally a positive indicator for the stock price in the short term. Investors often react favorably to earnings beats.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100